Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Share this content:
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with AEs, including cannabinoid hyperemesis syndrome.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with AEs, including cannabinoid hyperemesis syndrome.

Patients with cancer can develop a multitude of symptoms from both the disease and the associated chemotherapy and/or radiation treatments. Some of the most common symptoms can include pain, nausea, vomiting, weight loss, and lack of appetite. Some of the traditional medications used to treat pain such as opioid analgesics can be challenging to manage and also come with a potentially hazardous set of adverse events.

Cannabinoid-type medications have become increasingly popular over the last decade to help patients with cancer, most notably for chemotherapy-induced nausea and vomiting and appetite stimulation.1,2 The two most common products used in the United States include dronabinol and nabilone.1,2 These medications along with smoked marijuana have been used off-label for chronic pain in patients with cancer with mixed results.

A systematic review conducted by Penny F. Whiting, PhD, of the School of Social and Community Medicine in the United Kingdom and colleagues found a greater mean number of patients who showed a complete nausea and vomiting response (47% vs 20%, OR 3.82 [1.55-9.42]) compared with placebo.3 There was also a greater mean reduction in pain assessment (based on numerical scale) of -0.46 (95% CI, -0.80 to -0.11).  The overall reduction in pain was not statistically significant:  37% vs 31%, OR 1.41 (95% CI 0.99-2.00). A majority of the studies included in this review did show an overall “trend” towards certain symptom improvements in those receiving cannabinoids, but many of these results did not reach statistical significance. Common adverse events included dry mouth, nausea, vomiting and neurological effects (hallucinations, euphoria, drowsiness, confusion, loss of balance).

Another systematic review conducted by Shannon M. Nugent, PhD, of the VA Portland Health Care System in Oregon and colleagues specifically evaluated cannabis for chronic pain.4 The authors concluded that there is only low-strength evidence supporting the use of cannabis for chronic pain. There were also an increase in neurological side effects. The authors noted that there wasn't enough data at the time of their research to know what the long-term side effects may be. It is important to note that many of these studies and reviews do not solely include patients with cancer; therefore broad application of their results to those with cancer should be avoided.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs